In early June 2026, Legend Biotech reported early Phase 1 data for LB2501 in relapsed/refractory B-cell non-Hodgkin lymphoma, showing high response rates, durable in vivo CAR-T expansion without ...
In an ongoing Phase 1 study of 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, Legend Biotech's CAR-T cell therapy LB2501 demonstrated a 100% objective response rate and an 83% ...
SINGAPORE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind ...
Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T therapy, as an ...
Cell therapy company Aurion Biotech is moving forward with plans to IPO despite a pending lawsuit from one of its existing investors. The eye-disease-focused company plans to list on the New York ...
EUDA Health (EUDA) announced that it has entered into preliminary discussions with Guangdong Cell Biotech Co. to form a joint venture. Guangdong Cell Biotech develops autologous cell treatments and ...
With U.S. President Donald Trump’s tariffs, HC Wainwright analyst writes that investors are looking for companies with macroeconomic moats that protect against tariff exposure and regulatory ...
Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that it will present data on CTA313, its investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results